ISCNF - Isracann Biosciences to acquire Canadian natural health medicine developer

Isracann Biosciences (OTCPK:ISCNF) will acquire all shares in the capital of Praesidio for aggregate consideration of C$4M in common shares of the company. Praesidio Health is an industry-leading, Canadian medical research company that develops and validates natural health medicine using an evidence-based process.  The consideration shares will be issued in seven tranches, with C$1M of the consideration shares being issued at closing and C$500,000 being issued every six months thereafter until the third anniversary of the date of closing. Transaction closing is expected to occur on or about April 4th, 2022.

For further details see:

Isracann Biosciences to acquire Canadian natural health medicine developer